Carcinoma, Basal Cell Clinical Trial
Official title:
Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: Hexylaminolevulinate and Aminolevulinic Acid Nano Emulsion Versus Methylaminolevulinate
This pilot study compares three photosensitisers, hexylaminolevulinate (HAL) and aminolevulinic acid nano emulsion (BF-200 ALA) to methylaminolevulinate (MAL) in photodynamic therapy of superficially growing basal cell carcinomas. Study is conducted using randomised prospective double blinded comparing design. Fluorescence is measured in A.U. (Arbitrary Unit) with standardised set-up before and after the exposure. Efficacy is assessed clinically, histologically and by hyperspectral imaging system at 3 months, 12 months and 5 years.
Study recruits volunteering patients, who are referred to the department of dermatology and allergology, Päijät-Häme Central Hospital, Lahti, with 99 clinically assessed superficial basal cell carcinoma on the body area, not face and scalp. Diagnoses is confirmed histologically by punch biopsies and hyperspectral images are taken before the biopsies. The lesions are randomised in three groups: interventions HAL and BF-200 ALA and comparator MAL. Photodynamic therapy is given by the standard procedure. Fluorescence is measured in A.U. (Arbitrary Unit) with standardised set-up, with Wood's light, digital camera and a yellow lens, before and after the exposure. Pain is measured in VAS-scale before, during and after the exposure. Efficacy is assessed clinically, histologically and by hyperspectral imaging system at 3 months, 12 months and 5 years. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00875381 -
Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin
|
N/A | |
Recruiting |
NCT04362722 -
Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
|
Phase 2 | |
Completed |
NCT00218829 -
DMSO-PDT of BCC - A 6 Year Follow up
|
N/A | |
Completed |
NCT02674009 -
Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)
|
||
Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT02956889 -
To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01204073 -
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
|
Phase 1 | |
Completed |
NCT02029352 -
Topical Green Tea Ointment in Treatment of Superficial Skin Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT03569345 -
Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate
|
Phase 1/Phase 2 | |
Recruiting |
NCT05463757 -
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
|
||
Completed |
NCT00189280 -
Aldara for the Treatment of Large and/or Multiple sBCC
|
Phase 3 | |
Completed |
NCT03541252 -
Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT05133427 -
HIFU for Treatment of Non-nodular and Recurrent BCC
|
N/A | |
Completed |
NCT00007631 -
Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer
|
Phase 3 | |
Active, not recruiting |
NCT05138328 -
Laser Treatment of Basal Cell Carcinoma Under Imaging Guidance
|
N/A | |
Completed |
NCT03132636 -
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
|
Phase 2 | |
Completed |
NCT00847912 -
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
|
Phase 4 | |
Enrolling by invitation |
NCT02666833 -
Optical Imaging for Preoperative Delineation of Nonmelanoma Skin Cancers
|
N/A | |
Completed |
NCT01482104 -
New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)
|
N/A | |
Completed |
NCT01455363 -
Post-occlusive Reactive Hyperemia and Basal-cell Carcinoma
|
N/A |